Summary of COVID-19 P2Et studies
Hide extended summaries
RCT 91 hospitalized COVID-19 patients in Colombia showing no significant differences in clinical outcomes with P2Et treatment. P2Et treatment was associated with reduced pro-inflammatory cytokines (G-CSF, IL-5, IL-18) and increased NK cells and other immune populations.
Sep 2022, Frontiers in Medicine, https://www.frontiersin.org/articles/10.3389/fmed.2022.991873/full, https://c19p.org/uruena
1. Urueña et al., Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et)
91 patient P2Et late treatment RCT: 24% lower ICU admission (p=0.76) and 23% shorter hospitalization (p=0.12).RCT 91 hospitalized COVID-19 patients in Colombia showing no significant differences in clinical outcomes with P2Et treatment. P2Et treatment was associated with reduced pro-inflammatory cytokines (G-CSF, IL-5, IL-18) and increased NK cells and other immune populations.
Sep 2022, Frontiers in Medicine, https://www.frontiersin.org/articles/10.3389/fmed.2022.991873/full, https://c19p.org/uruena
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.